H.U. Group Holdings

H.U. Group Holdings, Inc., together with its subsidiaries, operates healthcare business in Japan, the United States, Europe, and internationally. The Lab Testing and Its Related Services segment provides general testing services to medical institutions that include esoteric testing, such as genetic and oncology testing; companion diagnostics-related tests for cancer treatment; omics analysis comprising whole genome sequencing and proteome analysis; comprehensive support for clinical trials and research, including pre-trial setup work, specimen collection and transport, measuring, result reports, and data management, as well as SaaS for general practitioners and personal health records. Its In-Vitro Diagnostics segment provides Lumipulse system products, an automated chemiluminescence enzyme immunoassay system that offers reagents; testing services for neurodegenerative diseases; and rapid diagnostics kit for infectious diseases comprising influenza and COVID-19, as well as cerebrospinal fluid reagent. This segment also develops blood-based reagents and biomarkers specifically for neurodegenerative diseases, such as Alzheimer's. The Healthcare-related Services segment offers in-house sterilization for central supply rooms in hospitals and external sterilization at sterilization centers; operating room support, endoscopy room support, medical equipment maintenance and inspection, and logistics management and transportation services; support for important tasks related to hospital administration work, including the sale of medical equipment, supplies, and consumables related to central supply rooms and operating rooms; bulk rentals of nursing care equipment, supplying equipment, including wheelchairs and nursing beds; and home medical care and nursing services. The company was formerly known as Miraca Holdings Inc. and changed its name to H.U. Group Holdings, Inc. in July 2020. H.U. Group Holdings, Inc. was incorporated in 1950 and is headquartered in Tokyo, Japan.